Listen on the go
CORRECT!
Next question
touchIMMUNOLOGY touchIMMUNOLOGY

Start Learning

Touch Loading image
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025 severe allergic reactions, including anaphylaxis
JOURNALS
Start Learning
Epinephrine Sublingual Film for Type 1 Allergic Reactions: Key data from #AAAAI2025
3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
JOURNALS
Start Learning
Clinical Approach to the Care of Patients with Immune Checkpoint Inhibitor-associated Inflammatory Arthritis
RGB-19 Matches Tocilizumab in Efficacy and Safety: Promising Phase III Data from RA Biosimilar Trial
JOURNALS
Start Learning
RGB-19 Matches Tocilizumab in Efficacy and Safety: Promising Phase III Data from RA Biosimilar Trial
Medics for Rare Disease
JOURNALS
Start Learning
Medics For Rare Disease – New Year, New Strategy
JOURNALS
Start Learning
New study reveals elevated cognitive impairment risk in rheumatoid arthritis patients, linked to inflammation and comorbidities
Mirikizumab, Crohn’s disease
JOURNALS
Start Learning
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
www.touchimmunology.com
JOURNALS
Start Learning
FDA approves bimekizumab for psoriatic arthritis, ankylosing spondylitis and axSpA
JOURNALS
Start Learning
Greatest Hits of 2024
Screening for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: Current Evidence and ACR 2023 Guideline Recommendations
JOURNALS
Start Learning
Screening for Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases: Muhammad Nisar, BSR 2025
The ACG American College of Gastroenterology’s 2025 Crohn’s disease guidelines
JOURNALS
Start Learning
What’s New in the 2025 ACG Crohn’s Disease Guidelines: Personalized Care and Advanced Therapies

to view Favourites, Keep Notes and Track CME Credits

Favourites
Medics For Rare Disease – New Year, New Strategy
View
New study reveals elevated cognitive impairment risk in rheumatoid arthritis patients, linked to inflammation and comorbidities
View
#EULAR2025 Sonelokimab Shows Promise in Improving PROs for Psoriatic Arthritis: Phase II ARGO Trial
View
Greatest Hits of 2024
View
Mirikizumab maintains efficacy in patients with Crohn’s disease previously treated with ustekinumab: One-year results from VIVID-2
View
Dr Vinod Ravindran joins touchREVIEWS in RMD Editorial Board – Bringing a Wealth of Knowledge in Clinical Rheumatology
View
Bridging Bench and Bedside: Future Leader, Dr Sonali Bracken on Autoimmunity, B Cell Research, and the Future of Rheumatology
View
Advances in the treatment of lupus and Sjögren’s disease
View
New data support the efficacy and safety of cendakimab in eosinophilic oesophagitis
View
Turning your Clinical Expertise into Business Success
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
Close Popup